Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company, has announced the granting of non-statutory stock options to two newly hired non-executive employees on August 1, 2024. The options cover 8,850 shares of common stock at an exercise price of $26.29 per share, matching the closing price on the Nasdaq Global Select Market on the grant date.
These grants were made under the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, and approved by the compensation committee. The options will vest over three years, with one-third vesting on each anniversary of the grant date, contingent on continuous service. The options expire after ten years and were granted as a material inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
Anika Therapeutics, Inc. (NASDAQ: ANIK), un'azienda globale di preservazione delle articolazioni, ha annunciato la concessione di opzioni su azioni non statutarie a due nuovi dipendenti non esecutivi il 1 agosto 2024. Le opzioni coprono 8.850 azioni ordinarie a un prezzo di esercizio di $26,29 per azione, corrispondente al prezzo di chiusura sul Nasdaq Global Select Market alla data di concessione.
Queste concessioni sono state effettuate sotto il Piano di Induzione Anika Therapeutics, Inc. 2021, come modificato, e approvato dal comitato di compensazione. Le opzioni si matureranno in tre anni, con un terzo che matura a ciascun anniversario della data di concessione, subordinato a un servizio continuativo. Le opzioni scadono dopo dieci anni e sono state concesse come un incentivo sostanziale per l'occupazione, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Anika Therapeutics, Inc. (NASDAQ: ANIK), una empresa global de preservación de articulaciones, ha anunciado la concesión de opciones sobre acciones no estatutarias a dos nuevos empleados no ejecutivos el 1 de agosto de 2024. Las opciones cubren 8,850 acciones ordinarias a un precio de ejercicio de $26.29 por acción, igualando el precio de cierre en el Nasdaq Global Select Market en la fecha de concesión.
Estas concesiones se realizaron bajo el Plan de Inducción Anika Therapeutics, Inc. 2021, según enmendado, y aprobado por el comité de compensación. Las opciones se adquirirán en un período de tres años, con un tercio adquiriéndose en cada aniversario de la fecha de concesión, sujeto a un servicio continuo. Las opciones expiran después de diez años y se otorgaron como un incentivo material para el empleo, de acuerdo con la Regla de Listado Nasdaq 5635(c)(4).
아니카 테라퓨틱스, Inc. (NASDAQ: ANIK)는 전 세계 관절 보존 회사로서 2024년 8월 1일 두 명의 신규 비상임 직원에게 비법정 주식 옵션을 부여했다고 발표했습니다. 이 옵션은 8,850주의 보통주를 행사 가격 $26.29에 제공하며, 이는 부여일의 나스닥 글로벌 선정 시장에서의 종가와 일치합니다.
이 부여는 수정된 아니카 테라퓨틱스, Inc. 2021 유도 계획에 따라 이뤄졌으며, 보상 위원회에 의해 승인되었습니다. 옵션은 3년 동안 분할 부여되며, 부여일의 매년 1/3씩 분할되어 제공되며, 지속적인 서비스에 따라 달라집니다. 옵션은 10년 후에 만료되며, Nasdaq 상장 규칙 5635(c)(4)에 따라 고용을 위한 실질적인 유인으로 부여되었습니다.
Anika Therapeutics, Inc. (NASDAQ: ANIK), une entreprise mondiale de préservation des articulations, a annoncé la concession de stock-options non statutaires à deux nouveaux employés non exécutifs le 1er août 2024. Les options concernent 8 850 actions ordinaires à un prix d'exercice de 26,29 $ par action, correspondant au prix de clôture sur le Nasdaq Global Select Market à la date d'octroi.
Ces octrois ont été réalisés dans le cadre du Plan d’Induction Anika Therapeutics, Inc. 2021, tel qu'amendé, et approuvé par le comité de rémunération. Les options deviendront acquises sur trois ans, un tiers devenant acquis à chaque anniversaire de la date d'octroi, sous réserve d'une continuité de service. Les options expirent après dix ans et ont été accordées comme une incitation matérielle à l'emploi, conformément à la règle d'inscription Nasdaq 5635(c)(4).
Anika Therapeutics, Inc. (NASDAQ: ANIK), ein globales Unternehmen zur Gelenkerhaltung, hat die Gewährung von nicht-statutären Aktienoptionen an zwei neu eingestellte nicht-executive Mitarbeiter am 1. August 2024 bekannt gegeben. Die Optionen decken 8.850 Aktien zum Ausübungspreis von $26,29 pro Aktie ab, was dem Schlusskurs am Nasdaq Global Select Market am Tag der Gewährung entspricht.
Diese Gewährungen wurden im Rahmen des Anika Therapeutics, Inc. 2021 Induktionsplans vorgenommen, wie geändert, und von dem Vergütungsausschuss genehmigt. Die Optionen werden über drei Jahre zugänglich sein, wobei ein Drittel an jedem Jahrestag des Gewährungsdatums verfügbar wird, abhängig von einer kontinuierlichen Dienstzeit. Die Optionen verfallen nach zehn Jahren und wurden als wesentliche Anreize für die Beschäftigung vergeben, gemäß der Nasdaq-Listing-Regel 5635(c)(4).
- Stock options granted as material inducement for new hires, potentially attracting talent
- Vesting schedule of options encourages employee retention over three years
- None.
BEDFORD, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on August 1, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 8,850 shares of common stock at a per share exercise price of
Of the shares covered by the Options, one-third will vest on each of the first three anniversaries of the grant date, in each case for so long as the grantee provides continuous service to Anika through the relevant vesting date.
Unless earlier terminated in accordance with their terms, the Options will expire on the tenth anniversary of the grant date and are otherwise subject to the terms and conditions of the equity award agreement approved by Anika. The Options were granted pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, which was not subject to stockholder approval.
About Anika
Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.
ANIKA, ANIKA THERAPEUTICS and the Anika logo are registered trademarks of Anika Therapeutics, Inc.
For Investor Inquiries:
Anika Therapeutics, Inc.
Mark Namaroff, 781-457-9287
Vice President, Investor Relations, ESG and Corporate Communications
investorrelations@anika.com
FAQ
How many shares of common stock are covered by the stock options granted by Anika Therapeutics (ANIK) on August 1, 2024?
What is the exercise price of the stock options granted by Anika Therapeutics (ANIK) on August 1, 2024?
What is the vesting schedule for the stock options granted by Anika Therapeutics (ANIK) on August 1, 2024?
Under which plan were the stock options granted by Anika Therapeutics (ANIK) on August 1, 2024?
